Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Millennium Pharmaceuticals, Inc. |
---|---|
Information provided by: | Millennium Pharmaceuticals, Inc. |
ClinicalTrials.gov Identifier: | NCT00297921 |
Prospective, nonrandomized, noncomparative, open-label, multicenter, 2-stage clinical study designed to determine the overall response (combined complete remission, complete remission with incomplete blood count recovery, partial remission, or blast response) rate following tandutinib therapy in 2 groups of patients with newly diagnosed Acute Myelogenous Luekemia.
Condition | Intervention | Phase |
---|---|---|
Acute Myelogenous Leukemia |
Drug: tandutinib |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Non-Randomized, Open Label, Active Control, Single Group Assignment |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Pretreatment laboratory test values as follows:
Receipt of prior antineoplastic therapy for leukemia, except that prior therapy with the following is allowed:
Receipt of prior antineoplastic therapy for MDS, except that prior therapy with the following is allowed:
Receipt of prior antineoplastic therapy for MPD, except that prior therapy with the following is allowed:
Study ID Numbers: | C03002 |
Study First Received: | February 27, 2006 |
Last Updated: | June 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00297921 |
Health Authority: | United States: Food and Drug Administration |
Leukemia Acute myelogenous leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Acute myelocytic leukemia |
Neoplasms Neoplasms by Histologic Type |